Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on decoding biology and chemistry through a combination of biology, chemistry, automation, data science, and engineering to accelerate drug discovery. The company operates in the United States and the United Kingdom and is advancing several drug candidates across early-stage development. Its pipeline includes REC-4881 for familial adenomatous polyposis, REC-617 for advanced solid tumors, REC-1245 for biomarker-enriched solid tumors and lymphoma, REC-3565 for relapsed or refractory B-cell malignancies, and REC-4539 for solid tumors and hematology oncology. Recursion also has preclinical programs such as REC-7735 for HR+ breast cancer and REC-102 for hypophosphatasia. The company has collaboration agreements with Roche & Genentech, Sanofi, Bayer AG, Tempus, and Takeda Pharmaceutical Company Limited. Incorporated in 2013, Recursion is headquartered in Salt Lake City, Utah, and its common stock trades on the NASDAQ under the symbol RXRX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RXRX
|
$3.90
|
27.8% Upside
|
Undervalued
|
$7.25
|
137.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-2.9x
|
1.6x
|
24.5x
|
1.534 B
|
1.047 B
|
4.5%
|
96.8%
|
-1.9
|
—
|
58.2%
|
